Summary of treatments performed in study mice.
|Group||Treatments (of 100 μL PBS)||Total sample size||Route of administration||Sample size in HIa||Sample size in CMIb||Sample size in challenges|
|II||100 μL PBS||25||Thigh muscle||3||9||10c, 6d|
|III||100 μg pVAX1||25||Thigh muscle||3||9||10c, 6d|
|IV||100 μg pVAX-IL33||25||Thigh muscle||3||9||10c, 6d|
|V||100 μg pVAX-ROP5||25||Thigh muscle||3||9||10c, 6d|
|VI||100 μg pVAX-ROP18||25||Thigh muscle||3||9||10c, 6d|
|VII||50 μg pVAX-ROP5 + 50 μg pVAX-ROP18||25||Thigh muscle||3||9||10c, 6d|
|VIII||33 μg pVAX-IL33 + 33 μg pVAX-ROP5 + 33 μg pVAX-ROP18||22||Thigh muscle||3||9||10c, 6d|
To assess humoral immunity (HI), sera were collected from the tail vein prior to immunization from three mice per group.
To assess cell-mediated immunity (CMI), through the lymphocyte proliferation assay (n = 3 mice), cytokine measurements (n = 3 mice), and flow cytometric analysis (n = 3 mice), spleens were aseptically removed from nine mice per group two weeks after the last immunization.
Two weeks after the final inoculation, the mice in all groups were challenged intraperitoneally with 1 × 103 tachyzoites of T. gondii RH strain.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.